AEMD net incomeQ1 2027-$1.55M
AEMD net income was -$1.55M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$1.76M a year earlier. For the full fiscal 2026 it was -$7.15M, compared with -$13.39M in fiscal 2025.
Aethlon Medical Inc. (AEMD) financials
For the twelve months ended Jun 30, 2026, Aethlon Medical Inc. reported -$6.94M of net income.
- Net income, TTM
- -$6.94M
- Cash
- $4.93M
- Market cap
- $8.8M
FY2017FY2024
FY2017FY2026
FY2017FY2026
AEMD revenue and earnings growth
AEMD EPSQ1 2027-$4.02
AEMD diluted EPS was -$4.02 in fiscal Q1 2027 (ended Jun 30, 2026). For the full fiscal 2026 it was -$10.61.
AEMD free cash flowQ1 2027-$1.91M
AEMD free cash flow was -$1.91M in fiscal Q1 2027 (ended Jun 30, 2026), compared with -$1.71M a year earlier. For the full fiscal 2026 it was -$7.00M, compared with -$7.65M in fiscal 2025.
Income statement
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | $0 | $574.2K | $294.2K | $659.1K | $650.2K | $229.6K | $149.6K | $392.1K |
| Research and development | $1.91M | $2.21M | $2.52M | $2.75M | $2.34M | $2.07M | $927.0K | $896.0K | $586.0K | $673.0K |
| Selling, general and admin | $2.70M | $3.24M | $3.90M | $4.48M | $3.46M | $2.46M | $1.55M | $953.5K | $792.6K | $849.5K |
| Operating income | -$7.29M | -$9.34M | -$12.64M | -$11.90M | -$10.42M | -$7.89M | -$5.93M | -$6.00M | -$4.83M | -$6.10M |
| Interest expense | $14.4K | $10.1K | - | - | - | - | - | - | - | - |
| Pre-tax income | -$7.15M | -$13.39M | - | - | - | - | - | - | - | - |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.15M | -$13.39M | -$12.21M | -$12.03M | -$10.42M | -$7.89M | -$6.37M | -$6.19M | -$5.68M | -$7.28M |
| EPS, basic | -$10.61 | -$85.77 | -$3109.60 | -$468.80 | -$568.00 | -$520.00 | -$1496.00 | -$4104.00 | -$1200.00 | -$11280.00 |
| EPS, diluted | -$10.61 | -$85.77 | -$3109.60 | -$468.80 | -$568.00 | -$520.00 | -$1496.00 | -$4104.00 | -$1200.00 | -$11280.00 |
| Diluted shares | 673,945 | 156,085 | 3,926.213 | 25,671.8 | 18,446.209 | 15,113.605 | 4,268.55 | 1,510.393 | 1,026.423 | 647.02 |
Balance sheet
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $5.03M | $5.60M | $5.53M | $14.62M | $17.16M | $9.91M | $9.60M | $3.83M | $6.97M | $1.56M |
| Receivables | - | - | - | $0 | $128.0K | $149.1K | $206.7K | $0 | $74.8K | $0 |
| Current assets | $5.57M | $5.95M | $6.23M | $15.09M | $18.16M | $10.35M | $10.04M | $4.04M | $7.23M | $1.60M |
| Total assets | $6.33M | $7.36M | $8.25M | $17.51M | $19.42M | $10.67M | $10.39M | $4.12M | $7.35M | $1.73M |
| Current liabilities | $1.45M | $1.90M | $1.83M | $1.51M | $1.82M | $1.38M | $1.07M | $1.82M | $478.0K | $611.8K |
| Long-term debt | - | - | - | - | - | - | - | $0 | $841.2K | $519.2K |
| Total debt | - | - | - | - | - | - | - | $0 | $841.2K | $519.2K |
| Total liabilities | $1.45M | $2.24M | $2.48M | $2.44M | $2.43M | $1.38M | $1.11M | $1.82M | $1.32M | $1.13M |
| Shareholders' equity | $4.89M | $5.12M | $5.77M | $15.06M | $16.99M | $9.29M | $9.28M | $2.30M | $6.03M | $595.4K |
Cash flow
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$7.00M | -$7.65M | -$10.13M | -$10.51M | -$9.77M | -$6.76M | -$5.20M | -$4.29M | -$3.91M | -$3.51M |
| Capital expenditures | $3.7K | $0 | $250.9K | $943.1K | $349.2K | $59.9K | $151.7K | $0 | $24.8K | $16.4K |
| Free cash flow | -$7.00M | -$7.65M | -$10.38M | -$11.45M | -$10.12M | -$6.82M | -$5.35M | -$4.29M | -$3.94M | -$3.52M |
| Investing cash flow | -$3.7K | $0 | -$250.9K | -$943.1K | -$349.2K | -$59.9K | -$151.7K | $0 | -$24.8K | -$16.4K |
| Financing cash flow | $6.52M | $7.73M | $1.29M | $8.91M | $17.37M | $7.13M | $11.13M | $1.15M | $9.35M | $2.96M |
| Stock-based compensation | $278.5K | $415.2K | $1.22M | $1.05M | $750.6K | $779.4K | $844.0K | $1.32M | $1.26M | $2.19M |
| Depreciation and amortization | $323.7K | $339.6K | $359.1K | $240.9K | $123.7K | $39.9K | $26.4K | $30.7K | $35.7K | $32.4K |
Key ratios
| Line item | Mar 31, 2026 | Mar 31, 2025 | Mar 31, 2024 | Mar 31, 2023 | Mar 31, 2022 | Mar 31, 2021 | Mar 31, 2020 | Mar 31, 2019 | Mar 31, 2018 | Mar 31, 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | - | - | -100.0% | 95.2% | -55.4% | 1.4% | 183.2% | 53.5% | -61.8% | -55.8% |
| Operating margin | - | - | - | -2072.0% | -3542.5% | -1197.3% | -912.0% | -2612.5% | -3228.8% | -1555.4% |
| Net margin | - | - | - | -2094.9% | -3540.9% | -1196.6% | -980.3% | -2697.8% | -3795.9% | -1855.8% |
| Free cash flow margin | - | - | - | -1993.6% | -3439.0% | -1035.5% | -822.7% | -1869.8% | -2630.2% | -898.4% |
| Return on equity | -146.4% | -261.3% | -211.7% | -79.9% | -61.3% | -84.9% | -68.7% | -269.4% | -94.1% | -1222.0% |
| Return on assets | -112.9% | -181.9% | -148.0% | -68.7% | -53.6% | -73.9% | -61.4% | -150.2% | -77.3% | -421.5% |
| Current ratio | 3.85 | 3.13 | 3.40 | 10.03 | 9.95 | 7.53 | 9.40 | 2.21 | 15.13 | 2.61 |
| Debt to equity | - | - | - | - | - | - | - | 0.00 | 0.14 | 0.87 |
Income statement
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $549.0K | $590.0K | $532.8K | $294.3K | $524.0K | $1.33M | $240.2K | $261.5K | $414.7K | $644.9K | $593.4K | $628.4K |
| Selling, general and admin | $662.5K | $698.0K | $741.6K | $521.4K | $735.4K | $718.0K | $816.4K | $958.4K | $752.0K | $764.9K | $979.2K | $850.8K |
| Operating income | -$1.58M | -$1.93M | -$2.06M | -$1.51M | -$1.79M | -$2.00M | -$1.81M | -$2.90M | -$2.62M | -$2.49M | -$3.57M | -$3.18M |
| Net income | -$1.55M | -$1.88M | -$2.02M | -$1.49M | -$1.76M | -$6.25M | -$1.75M | -$2.81M | -$2.57M | -$2.43M | -$3.47M | -$3.03M |
| EPS, basic | -$4.02 | - | -$2.45 | -$3.74 | -$42.42 | - | -$10.05 | -$16.11 | -$220.80 | - | -$109.60 | -$97.60 |
| EPS, diluted | -$4.02 | - | -$2.45 | -$3.74 | -$42.42 | - | -$10.05 | -$16.11 | -$220.80 | - | -$109.60 | -$97.60 |
| Diluted shares | 384,705 | - | 823,126 | 397,513 | 41,529 | - | 174,529 | 174,220 | 11,653.1 | - | 31,456.388 | 31,045.613 |
Balance sheet
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $4.93M | $5.03M | $6.96M | $5.85M | $3.77M | $5.60M | $4.83M | $6.86M | $9.07M | $5.53M | $7.97M | $10.18M |
| Current assets | $5.61M | $5.57M | $7.14M | $6.25M | $4.05M | $5.95M | $4.97M | $7.14M | $9.55M | $6.23M | $8.25M | $10.49M |
| Total assets | $6.24M | $6.33M | $8.06M | $7.32M | $5.31M | $7.36M | $6.53M | $8.85M | $11.42M | $8.25M | $10.44M | $12.83M |
| Current liabilities | $1.04M | $1.45M | $1.26M | $1.40M | $1.63M | $1.90M | $1.77M | $2.33M | $2.13M | $1.83M | $2.10M | $1.71M |
| Total liabilities | - | $1.45M | $1.34M | $1.58M | $1.88M | $2.24M | $2.19M | $2.83M | $2.70M | $2.48M | $2.83M | $2.51M |
| Shareholders' equity | $5.20M | $4.89M | $6.71M | $5.75M | $3.42M | $5.12M | $4.33M | $6.02M | $8.71M | $5.77M | $7.61M | $10.32M |
Cash flow
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$1.90M | -$1.75M | -$1.87M | -$1.66M | -$1.71M | -$1.67M | -$2.01M | -$2.21M | -$1.75M | -$2.57M | -$2.38M | -$2.70M |
| Capital expenditures | $9.2K | $2.1K | - | - | $0 | -$2.2K | $2.2K | $0 | $0 | $4.9K | $8.8K | $6.8K |
| Free cash flow | -$1.91M | -$1.75M | - | - | -$1.71M | -$1.67M | -$2.01M | -$2.21M | -$1.75M | -$2.57M | -$2.39M | -$2.71M |
| Investing cash flow | -$9.2K | -$2.1K | - | - | $0 | $2.2K | -$2.2K | $0 | $0 | -$4.9K | -$8.8K | -$6.8K |
| Financing cash flow | $1.82M | -$196.5K | $2.98M | $3.74M | -$5.4K | $2.36M | -$7.1K | -$3.8K | $5.38M | $42.6K | $177.1K | -$9.8K |
| Stock-based compensation | $50.0K | $61.2K | $72.4K | $72.4K | $72.4K | $72.4K | $90.0K | $113.5K | $139.3K | $139.1K | $573.0K | $257.2K |
| Depreciation and amortization | $72.9K | $79.5K | $81.6K | $79.9K | $82.6K | $83.9K | $83.8K | $85.8K | $86.1K | $85.8K | $91.5K | $91.4K |
Key ratios
| Line item | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 5.42 | 3.85 | 5.68 | 4.45 | 2.49 | 3.13 | 2.80 | 3.06 | 4.49 | 3.40 | 3.93 | 6.13 |
Source: XBRL data Aethlon Medical Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 1-for-15, first reported Nov 1, 2019; 1-for-10, first reported Nov 14, 2023; 1-for-80, first reported Nov 12, 2025.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
AEMD peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| AEMD | - | - | -$6.94M | - | $8.8M |
| CTSO | $37.22M | +3.1% | -$18.21M | -48.9% | $18.4M |
| BAX | $11.61B | +5.3% | -$723.00M | -6.2% | $13.66B |
| FMS | €19.63B | +1.5% | €978.37M | 5.0% | $12.82B |
AEMD FAQ
4 questionsIs AEMD profitable?
No. Aethlon Medical Inc. reported a net loss of $6.94M for the twelve months ended Jun 30, 2026.How much cash and debt does AEMD have?
Aethlon Medical Inc. reported $4.93M in cash and cash equivalents on its most recent balance sheet in SEC filings.When did AEMD last report financial results?
The latest statements here come from Aethlon Medical Inc.'s 10-Q filed on Aug 13, 2026, covering the period ended Jun 30, 2026.Where does this AEMD financial data come from?
Quantisnow builds these statements from the structured XBRL data Aethlon Medical Inc. files with the SEC. It is provided for information only and is not investment advice.